News

Ligand Pharmaceuticals Spins Off Pelican Technology Holdings and Merges with Primordial Genetics

1 Mins read

Ligand Pharmaceuticals recently announced its decision to spin off its subsidiary, Pelican Technology Holdings, and merge it with Primordial Genetics. The newly formed private company, called Primrose Bio, will primarily focus on the field of synthetic biology.

As part of the deal, Ligand will maintain ownership of the existing commercial royalties associated with the Pelican Expression Technology and hold a 49.9% stake in the merged entity.

In addition to this, Ligand will be contributing $15 million to Primrose Bio in exchange for a portion of the economic rights to certain products. While this divestiture will result in lower contract revenue for Ligand in the current year, it is expected to have a positive impact on the company’s adjusted earnings.

Ligand’s full-year revenue forecast now stands at $124 million to $126 million, as compared to the previous guidance of $124 million to $128 million. The company also anticipates adjusted earnings per share for the full year to be in the range of $5.10 to $5.25, surpassing the previous forecast of $4.85 to $5.

Related posts
News

SIM Mining Announces Global Launch of Next-Gen Cloud Mining Platform!

1 Mins read
London, UK, July 14, 2025 (GLOBE NEWSWIRE) — Revolutionizing Crypto Income: No Hardware, No Hassle – Just Daily Profits. In today’s fast-growing…
News

RICH Miner leads the Ripple cloud mining revolution - converting XRP into daily stable income

3 Mins read
WinnerMining free cloud mining APP helps zero-investment users earn BTC and XRP! Turn your phone into a mining machine There is no…
News

GCCI hosts strategic meeting with APMIA Chairman - Daily Times

1 Mins read
The Gujranwala Chamber of Commerce and Industry (GCCI) recently hosted a strategic meeting with Muhammad Bilal Khan, Chairman of the All Pakistan…

Leave a Reply

Your email address will not be published. Required fields are marked *